Brokerages Expect Meridian Bioscience, Inc. (VIVO) Will Post Earnings of $0.15 Per Share

Share on StockTwits

Equities research analysts expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to post $0.15 earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Meridian Bioscience’s earnings, with the highest EPS estimate coming in at $0.15 and the lowest estimate coming in at $0.14. Meridian Bioscience posted earnings of $0.21 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 28.6%. The business is scheduled to report its next earnings report before the market opens on Tuesday, April 30th.

On average, analysts expect that Meridian Bioscience will report full-year earnings of $0.63 per share for the current fiscal year, with EPS estimates ranging from $0.61 to $0.65. For the next year, analysts expect that the company will post earnings of $0.70 per share, with EPS estimates ranging from $0.66 to $0.73. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Thursday, January 24th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. Meridian Bioscience had a net margin of 12.06% and a return on equity of 19.17%. The business had revenue of $51.48 million for the quarter, compared to analyst estimates of $51.50 million. During the same period last year, the business posted $0.15 earnings per share. The firm’s quarterly revenue was down 1.5% on a year-over-year basis.

A number of equities research analysts recently commented on the stock. ValuEngine lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Saturday. Canaccord Genuity lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating and dropped their price objective for the stock from $17.00 to $11.00 in a report on Wednesday, April 3rd. Zacks Investment Research lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Saturday, April 6th. BidaskClub upgraded shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Friday, March 29th. Finally, Robert W. Baird dropped their price objective on shares of Meridian Bioscience from $17.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, April 3rd. Four investment analysts have rated the stock with a sell rating and two have assigned a hold rating to the company’s stock. The company presently has a consensus rating of “Sell” and a consensus target price of $14.75.

A number of hedge funds have recently modified their holdings of VIVO. Norges Bank acquired a new stake in Meridian Bioscience in the 4th quarter valued at $22,052,000. Vaughan Nelson Investment Management L.P. acquired a new stake in Meridian Bioscience in the 4th quarter valued at $13,297,000. BlackRock Inc. increased its stake in Meridian Bioscience by 5.6% in the 3rd quarter. BlackRock Inc. now owns 6,228,616 shares of the company’s stock valued at $92,806,000 after buying an additional 327,584 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in Meridian Bioscience in the 4th quarter valued at $3,724,000. Finally, Morgan Stanley increased its stake in Meridian Bioscience by 57.7% in the 3rd quarter. Morgan Stanley now owns 523,950 shares of the company’s stock valued at $7,807,000 after buying an additional 191,623 shares during the last quarter. Hedge funds and other institutional investors own 93.06% of the company’s stock.

Shares of NASDAQ:VIVO opened at $12.86 on Friday. Meridian Bioscience has a 12 month low of $12.70 and a 12 month high of $19.84. The company has a current ratio of 6.75, a quick ratio of 4.72 and a debt-to-equity ratio of 0.24. The firm has a market cap of $554.06 million, a P/E ratio of 17.38 and a beta of 0.49.

About Meridian Bioscience

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Read More: Trading Options- What is a Strangle?

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bibox Token  Tops 24-Hour Trading Volume of $2.78 Million
Bibox Token Tops 24-Hour Trading Volume of $2.78 Million
Ontology  Trading Up 0.7% This Week
Ontology Trading Up 0.7% This Week
DeepBrain Chain 24 Hour Trading Volume Tops $365,332.00
DeepBrain Chain 24 Hour Trading Volume Tops $365,332.00
Bitcoin Cash Tops One Day Trading Volume of $1.62 Billion
Bitcoin Cash Tops One Day Trading Volume of $1.62 Billion
Giant  Achieves Market Capitalization of $359,854.00
Giant Achieves Market Capitalization of $359,854.00
Kambria Price Hits $0.0026 on Major Exchanges
Kambria Price Hits $0.0026 on Major Exchanges


© 2006-2019 Ticker Report